Three new series of N`-(aryl or heteroarylmethylidene)-2-(1H-1,2,4-triazolo[2,3-
a]benzimidazol-2-ylsulfanyl) acetohydrazides (4a-k), N`-(α-arylethylidene)-2-(1H-1,2,4-
triazolo[2,3-a]benzimidazol-2-ylsulfanyl) acetohydrazides (5a-d), and 2-({[5-(alkyl or
aralkylsulfanyl)-1,3,4-oxadiazol-2-yl]methyl}sulfanyl)-1H-1,2,4-triazolo[2,3-a]benzimidazoles
(7a-e) were synthesized. Reaction of compound (1) with methyl bromoacetate afforded (2),
which when refluxed with hydrazine hydrate yielded (3). The latter was condensed with
aromatic aldehydes and substituted acetophenones to afford compounds (4a-k) and (5a-d)
respectively. Treatment of compound (3) with carbon disulfide in the presence of potassium
hydroxide resulted in the formation of (6). The latter was alkylated with the appropriate alkyl or
aralkyl halides to afford compounds (7a-e). The purity of all new compounds was checked by
TLC and elucidation of their structures was confirmed by IR, 1HNMR, and mass spectrometry
along with elemental microanalyses. All the target compounds were evaluated for their in-vitro
antimicrobial and in-vivo anti-inflammatory activities in comparison with ampicillin,
fluconazole, and indomethacin as reference drugs respectively. In addition to molecular
docking of compound 5c was performed.